Search
for

    Research

    5 / 1000+ results
      Index

      research Index

      January 2019
      Telogen Effluvium: A Review of Acute and Chronic Forms

      research Telogen effluvium

      67 citations , January 2013 in “Indian Journal of Dermatology, Venereology and Leprology”
      Chronic Telogen Effluvium may resolve after years and is diagnosed by examining the patient's history and clinical signs, with treatment aimed at underlying causes and possibly minoxidil.
      Toward a Diagnostic Score in Cushing's Syndrome

      research Toward a Diagnostic Score in Cushing's Syndrome

      42 citations , November 2019 in “Frontiers in Endocrinology”
      The document suggests creating a validated score to diagnose Cushing's Syndrome and considers plasma steroid profiling as a simpler diagnostic method.

    Community Join

    5 / 1000+ results

      community ABS-201 Trial - What should I know going in

      in Research/Science  26 upvotes 1 month ago
      The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

      community Allergan recruiting for Setipiprant trial in the US

       12 upvotes 8 years ago
      The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

      community Anagenic is trying to compound Gt20029

      in Treatment  58 upvotes 3 years ago
      The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

      community Best Treatment In The Pipeline?

      in Chat  15 upvotes 1 year ago
      New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.